Detection of hypoxia with 18F-fluoromisonidazole ( 18F-FMISO) PET/CT in suspected or proven pancreatic cancer

Clinical Nuclear Medicine

Volumn 38, Issue 1, 2013, Pages 1-6

  Segard, Tatiana ^a   Robins, Peter D ^a   Yusoff, Ian F ^a   Ee, Hooi ^a   Morandeau, Laurence ^a   Campbell, Elaine M ^a   Francis, Roslyn J ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

18F fluoromisonidazole; hypoxia; pancreatic carcinoma; PET CT

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18; MISONIDAZOLE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; HYPOXIA; MALE; PANCREAS CARCINOMA; CELL HYPOXIA; CLINICAL TRIAL; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING;

ADULT; AGED; CELL HYPOXIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MISONIDAZOLE; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84871648520     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182708777     Document Type: Article

References (24)

1. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/ csr/1975-2008/, based on November 2010 SEER data submission. SEER web site, 2011.
2. Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenvironment. Int J Cancer. 2007;121:699-705. (Pubitemid 47106197)
3. Onozuka H, Tsuchihara K, Esumi H. Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci. 2011;102:975-982.
4. Buchler P, Reber HA, Lavey RS, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res. 2004;120:295-303. (Pubitemid 38834199)
5. 18F-fluoromisonidazole. Semin Nucl Med. 2007;37:451-461. (Pubitemid 47498258)
6. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638-648.
7. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066-4074. (Pubitemid 47492951)
8. Prox D, Becker C, Pirie-Shepherd SR, et al. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg. 2003;27:405-411. (Pubitemid 36920111)
9. Philip PA. Targeting angiogenesis in pancreatic cancer. Lancet. 2008;371: 2062-2064.
10. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48:919-922.
11. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104. (Pubitemid 46622121)
12. 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-408.
13. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
14. 18F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36:1565-1573.
15. Wang W, Reiser-Erkan C, Michalski CW, et al. Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2010;401:422-428.
16. Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor- 1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1-e9. (Pubitemid 351440946)
17. Hicks RJ, Rischin D, Fisher R, et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005;32:1384-1391. (Pubitemid 41746841)
18. Rasey JS, Nelson NJ, Chin L, et al. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301-308. (Pubitemid 20214420)
19. Chang Q, Jurisica I, Do T, et al. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res. 2011;71:3110-3120.
20. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
21. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260. (Pubitemid 43073432)
22. Mees G, Dierckx R, Vangestel C, et al. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging. 2009;36:1674-1686.
23. Grassetto G, Rubello D. Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol. 2011;34: 111-114.
24. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/ computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243. (Pubitemid 41033440)